PMID- 24994553
OWN - NLM
STAT- MEDLINE
DCOM- 20151016
LR  - 20211021
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 232
IP  - 1
DP  - 2015 Jan
TI  - Altered BDNF is correlated to cognition impairment in schizophrenia patients with 
      tardive dyskinesia.
PG  - 223-32
LID - 10.1007/s00213-014-3660-9 [doi]
AB  - BACKGROUND: Long-term antipsychotic treatment for schizophrenia is often 
      associated with the emergence of tardive dyskinesia (TD), which is linked to 
      greater cognitive impairment. Brain-derived neurotrophic factor (BDNF) plays a 
      critical role in cognitive function, and schizophrenia patients with TD have 
      lower BDNF levels than those without TD. OBJECTIVE: This study examines the BDNF 
      levels, the cognitive function, and the association of BDNF with cognitive 
      function in schizophrenia patients with or without TD. METHODS: We recruited 83 
      male chronic patients with (n=35) and without TD (n=48) meeting DSM-IV criteria 
      for schizophrenia and 52 male control subjects. We examined the Repeatable 
      Battery for the Assessment of Neuropsychological Status (RBANS) and BDNF levels 
      for all subjects. Positive and Negative Symptom Scale (PANSS) and the Abnormal 
      Involuntary Movement Scale (AIMS) were assessed in patients. RESULTS: BDNF levels 
      were lower in patients with than those without TD (p<0.05). RBANS total score 
      (p<0.01) and subscales of immediate memory, visuospatial/constructional 
      performance, and attention were lower in patients with than those without TD (all 
      p<0.05). BDNF levels were positively associated with immediate memory in patients 
      without TD, but negatively in TD patients (both p<0.05). Multiple regression 
      analysis confirmed that in either TD or non-TD group, BDNF was an independent 
      contributor to immediate memory (both p<0.05). CONCLUSIONS: BDNF may be involved 
      in the pathophysiology of TD. While the associations between BDNF and cognition 
      in both TD and non-TD patients suggest a close relationship between BDNF and 
      cognition, the different directions may implicate distinct mechanisms between TD 
      and non-TD patients.
FAU - Wu, Jing Qin
AU  - Wu JQ
AD  - School of Biomedical Sciences and Pharmacy, Faculty of Health, The University of 
      Newcastle, University Drive, Callaghan, NSW, 2308, Australia.
FAU - Chen, Da Chun
AU  - Chen DC
FAU - Tan, Yun Long
AU  - Tan YL
FAU - Tan, Shu Ping
AU  - Tan SP
FAU - Hui, Li
AU  - Hui L
FAU - Lv, Men Han
AU  - Lv MH
FAU - Soares, Jair C
AU  - Soares JC
FAU - Zhang, Xiang Yang
AU  - Zhang XY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140704
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antipsychotic Agents/adverse effects/therapeutic use
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Cognition Disorders/*blood/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Movement Disorders/*blood/epidemiology
MH  - Neuropsychological Tests
MH  - Schizophrenia/*blood/drug therapy/epidemiology
EDAT- 2014/07/06 06:00
MHDA- 2015/10/17 06:00
CRDT- 2014/07/05 06:00
PHST- 2014/04/05 00:00 [received]
PHST- 2014/06/03 00:00 [accepted]
PHST- 2014/07/05 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2015/10/17 06:00 [medline]
AID - 10.1007/s00213-014-3660-9 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2015 Jan;232(1):223-32. doi: 
      10.1007/s00213-014-3660-9. Epub 2014 Jul 4.